SAR and Pharmacokinetic Studies of Sotrastaurin (AEB071), a Promising Novel Medicine to Prevent Graft Rejection and Treat Psoriasis
Wagner, Juergen, Von Matt, Peter, Faller, Bernard, Cooke, Nigel Graham, Albert, Rainer, Sedrani, Richard, Beerli, Christian, Weckbecker, Gisbert, Evenou, Jean-Pierre, Zenke, Gerhard and Cottens, Sylvain (2011) SAR and Pharmacokinetic Studies of Sotrastaurin (AEB071), a Promising Novel Medicine to Prevent Graft Rejection and Treat Psoriasis. Journal of Medicinal Chemistry, 54 (17). pp. 6028-6039. ISSN 0022-2623
Abstract
Protein kinase C (PKC) isotypes have emerged as a key novel target for the blockade of early T-cell activation. Herein, we report on the structure-activity relationship as well as the detailed physicochemical and in vivo pharmacokinetic properties of Sotrastaurin (AEB071, 1), a novel maleimide-based PKC inhibitor. The selective uptake of Sotrastaurin into lymphatic tissues might contribute to its in vivo efficacy and favorable therapeutic safety margin. Sotrastaurin is the first PKC inhibitor to show beneficial effects in patients suffering from psoriasis or to prevent graft rejection in transplanted patients in Phase II clinical trials.
Item Type: | Article |
---|---|
Related URLs: | |
Additional Information: | archiving not formally supported by this publisher |
Related URLs: | |
Date Deposited: | 13 Oct 2015 13:15 |
Last Modified: | 13 Oct 2015 13:15 |
URI: | https://oak.novartis.com/id/eprint/4420 |